Global Mycosis Fungoides Treatment Market is segmented By Phase (Premycotic Phase, Patch Phase, Plaque Phase, Tumor Phase, Others) By Drug Class (Topical Corticosteroids, Topical Nitrogen Mustards, Topical Bexarotene, Others) By Therapy (Radiation Therapy, Immunotherapy, Photodynamic Therapy, Chemotherapy, Others) By End Users (Hospitals, Oncology centers, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Global Mycosis Fungoides Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2031 growing with a CAGR of YY% during the forecast period 2024-2031.
Mycosis fungoides occur when lymphocytes become cancerous and affect the skin. Mycosis fungoides belongs to a rare type of cancer called cutaneous T-cell lymphoma. The global mycosis fungoides treatment market has witnessed significant growth in recent years due to the adoption of electron beam therapy treatments by using the agents such as interferon alpha, bexarotene, or methotrexate.
Furthermore, significant growth drivers such as the increasing prevalence of cutaneous T-cell lymphoma cancers, and rising research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Merck & Co., Kyowa Kirin Ltd., Bristol Myers Squibb, and others are actively operating in the market.
Market Scope
| Metrics | Details |
| CAGR | YY% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Phase, Drug Class, Therapy, End Users |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
For more details on this report - Request for Sample
Market Dynamics
Increasing Technological Advancements for Mycosis Fungoides Treatment are Expected to Boost the Market Growth
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma and the major technological advancements from major companies help to drive the market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with mycosis fungoides.
For instance, in September 2022, CRISPR Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, allogeneic CAR T cell therapy targeting CD70 for the treatment of Mycosis Fungoides and Sezary Syndrome. Thus, the above factors help to boost the market growth in the forecast period.
Rising Research and Developments for Mycosis Fungoides Treatment
The global mycosis fungoides treatment market has witnessed significant growth due to various recent research and developments. Mycosis fungoides are usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating mycosis fungoides help to accelerate market growth.
For instance, in June 2023, Innate Pharma S.A S.A. announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides are presented at the 17th International Conference on Malignant Lymphoma. Lacutamab is the first anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for the treatment of cutaneous T-cell lymphoma. Thus, owing to the above factors the market is expected to boost over the forecast period.
Complications Associated with Mycosis Fungoides are Expected to Hamper Global Market Growth
Individuals with mycosis fungoides are at a higher risk of developing secondary malignancies such as hodgkin lymphoma, chronic leukemia, and lung cancer. Additionally, the treatment with topical HN2 therapy can cause hypersensitivity reactions and result in hypopigmentation or hyperpigmentation of treated areas. Thus, owing to the above factors the market is expected to hamper over the forecast period.
Segment Analysis
The global mycosis fungoides treatment market is segmented based on phase, drug class, therapy, end users and region.
Radiation Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Mycosis Fungoides Treatment Market Share
The rising clinical trials of radiation therapy globally have contributed to the growing demand for mycosis fungoides treatment. Radiotherapy involves the use of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor. Stereotactic radiosurgery technology is the common radiation therapy that uses many small gamma rays to deliver a precise dose of radiation to the target tumor cell.
For instance, according to clinicalTrials.gov, on June 2, 2023, M.D. Anderson Cancer Center conducted a clinical trial on Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides. The aim is to evaluate the efficacy of low-dose radiation in the management of cutaneous mycosis fungoides measured as any local control for each lesion after the treatment in patients with stage IA - IVB cutaneous mycosis fungoides. Thus, the above factors help to accelerate the market growth.
Geographical Penetration
North America Accounted for Approximately 41.4% of the Market Share in 2022
North America has maintained a significant proportion of the mycosis fungoides treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as increasing research and developments, rising prevalence of cutaneous T-cell lymphoma, and technological advancements in mycosis fungoides treatment.
For instance, in August 2023, Soligenix, Inc. announced that patient enrollment has been opened for the investigator-initiated study (IIS) at the University of Pennsylvania, supported by a $2.6 million Orphan Products Development grant award by the U.S. Food and Drug Administration (FDA). The treatment involves the HyBryte (synthetic hypericin) in patients with mycosis fungoides, an early-stage cutaneous T-cell lymphoma. Thus, the above factors help to boost the region's growth.
Competitive Landscape
The major global players in the market include Merck & Co., Tocris Bioscience, Bristol Myers Squibb, Jubilant Cadista Pharmaceuticals Inc., Pfizer Inc., Kyowa Kirin Ltd., Bauch Health, Innate Pharma S.A, Helsinn Therapeutics, and Curia among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the mycosis fungoides treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in mycosis fungoides treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the mycosis fungoides treatment market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the mycosis fungoides treatment market is expected to be moderately affected over the forecast period.
Key Developments
- In Kyowa Kirin, Inc. announced an initiative, Proactively Recognizing Occurrence in Blood through Education (PROBE) housed on PROBEinCTCL.com which was developed to educate healthcare providers on the importance of assessing blood involvement in Sezary Syndrome and Mycosis Fungoides.
- In July 2023, AbbVie announced that Venetoclax is under clinical development Phase II for Transformed Mycosis Fungoides. Venetoclax acts as an antineoplastic agent and is formulated as film-coated tablets and coated tablets for oral route of administration.
- In September 2022, Helsinn Group and Juniper Biologics Pte Ltd. announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market, and sell LEDAGA (chlormethine gel) in Australia, Asia, and the Middle East as a topical treatment of mycosis fungoides, a type cutaneous T-cell lymphoma in adults.
Why Purchase the Report?
- To visualize the global mycosis fungoides treatment market segmentation based on the phase, drug class, therapy, end users and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global mycosis fungoides treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global mycosis fungoides treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
